Davunetide (NAP, AL-108) is an intranasal peptide that stabilized microtubules and reduced tau phosphorylation in preclinical studies; in a 52-week phase 2/3 trial in 313 people with progressive supranuclear palsy it did not differ from placebo on either primary measure.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Davunetide' with aliases NAP, NAPVSIPQ, AL-108, AL-208, ADNF fragment, activity-dependent neuroprotective protein fragment · 2026-09-27 12:04 · somebody
kind set kind set to peptide: palette r2 · 2026-09-27 12:04 · somebody
fact added summary: Davunetide (NAP, AL-108) is an intranasal peptide that stabilized microtubules and reduced tau phosphorylation in precli · 2026-09-27 12:04 · somebody
fact added summary: In a 12-week trial in 63 people with schizophrenia, davunetide did not significantly change cognition against placebo bu · 2026-09-27 12:04 · somebody
citation added pmid 24873720 cited as established: Davunetide was not effective in progressive supranuclear palsy (phase 2/3 RCT) · 2026-09-27 12:04 · somebody
citation added pmid 22169248 cited as emerging: Davunetide in schizophrenia: no cognitive effect, functional capacity improved (RCT, n=63) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.